Related Experiment Videos
[Multicenter clinical study and pharmacokinetics of ceftazidime in children and newborn infants]
Insights
Ceftazidime, a new cephalosporin, is effective and safe for treating severe pediatric infections, including neonatal sepsis and meningitis. Recommended dosages vary by age and condition, with higher doses for cystic fibrosis and immunocompromised patients.
Area of Science:
- Pharmacology
- Pediatric Infectious Diseases
- Antimicrobial Therapy
Context:
- Ceftazidime is a third-generation cephalosporin antibiotic with notable activity against Pseudomonas aeruginosa.
- Pediatric patients, including neonates, often present unique challenges in managing severe bacterial infections.
Purpose:
- To evaluate the pharmacokinetics and clinical efficacy of ceftazidime in pediatric populations.
- To establish appropriate dosing guidelines for neonates, infants, children, and specific high-risk groups.
Summary:
- Ceftazidime demonstrated efficacy and safety in treating severe pediatric infections such as neonatal septicemia, meningitis, and urinary tract infections caused by multiresistant bacteria.
- It is also effective for empirical therapy in febrile immunocompromised children and acute exacerbations in cystic fibrosis patients.
- Recommended dosages are 30-50 mg/kg every 8 hours for children and 30 mg/kg every 12 hours for neonates, with adjustments for severe cases.
Impact:
- Provides evidence for the use of ceftazidime in pediatric infectious disease management.
- Offers practical dosing recommendations to optimize treatment outcomes and safety in neonates and children.
- Supports the consideration of ceftazidime as a key therapeutic option for challenging pediatric bacterial infections.
Abstract:
The pharmacokinetics and clinical efficacy of ceftazidime, a new cephalosporin with activity against Pseudomonas aeruginosa, were studied in children and neonates. Our studies suggest that ceftazidime should be considered for the treatment of sever infections in pediatric patients (neonatal septicemia and meningitis, urinary tract infections due to multiresistant bacteria) and for the empirical therapy of febrile episodes in immunocompromised children. Ceftazidime appears to be effective and safe, alone or associated with an aminoglycoside, in the treatment of acute exacerbation in cystic fibrosis. The dosage recommended on the basis of our pharmacokinetic studies is 30 to 50 mg/kg intravenously every eight hours for infants and children and 30 mg/kg every 12 hours for neonates. Larger doses should be used in cystic fibrosis patients, immunosuppressed children, meningitis, and bacterial infections due to organisms with high MICs.